Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Z

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Provides Better Outcome Than Targeted Therapy in Partial Response Patients and Better RFS

By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
21 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Featured Video

19:25
Pfizer Hematology

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip
Skin
14:32

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

32 views
06:35

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Xth Eurasian Hematology-Oncology Congress

Z. Turna

21 views
21:19

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Xth Eurasian Hematology-Oncology Congress

S. Seber

252 views
05:25

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

29 views
15:44

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Xth Eurasian Hematology-Oncology Congress

D. Erdem

44 views